Trial Profile
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms MERIT
- 22 Jan 2024 Planned End Date changed from 31 Dec 2024 to 15 Jan 2026.
- 22 Jan 2024 Planned primary completion date changed from 3 Dec 2023 to 21 Dec 2024.
- 13 Oct 2023 Planned End Date changed from 15 Jan 2025 to 31 Dec 2024.